-
Innovation Ranking
NewInnovation Ranking – Poseida Therapeutics Inc
Poseida Therapeutics Inc (Poseida Therapeutics) is a biopharmaceutical company. It harnesses its proprietary gene engineering platform, to develop next generation cell and gene therapeutics to treat solid tumors and hematological malignancies. The company is investigating its lead product candidate P-BCMA-101, an autologous CAR-T therapy against refractory multiple myeloma. It is also evaluating P-PSMA-101 and P-PSMA-ALL01, allogeneic chimeric antigen receptors for the treatment of prostate cancer; and Dual car (CD19/CD20) targeting solid tumor. Poseida Therapeutics is headquartered in San Diego, California,...
-
Product Insights
NewNet Present Value Model: Poseida Therapeutics Inc’s PMUC1CALLO-1
Empower your strategies with our Net Present Value Model: Poseida Therapeutics Inc's PMUC1CALLO-1 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dazukibart in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dazukibart in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dazukibart in Systemic Lupus Erythematosus Drug Details: Dazukibart (PF-06823859) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Irinotecan Hydrochloride in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Irinotecan Hydrochloride in Osteosarcoma Drug Details: Irinotecan Hydrochloride (Onivyde) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Ovarian Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Colorectal Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Kidney Cancer (Renal Cell Cancer) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Gastric Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Solid Tumor Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Esophageal Cancer Drug Details: P-MUC1CALLO-1 is under development for...